Περίληψη:
A serosurvey of IgG antibodies against SARS-CoV-2 was conducted in Greece between May and August 2020. It was designed as a cross-sectional survey and was repeated at monthly intervals. The leftover sampling methodology was used and a geographically stratified sampling plan was applied. Of 20,110 serum samples collected, 89 (0.44%) were found to be positive for anti-SARS-CoV-2 antibodies, with higher seroprevalence (0.35%) observed in May 2020. The highest seroprevalence was primarily observed in the “30–49” year age group. Females presented higher seroprevalence compared to males in May 2020 (females: 0.58% VS males: 0.10%). This difference reversed during the study period and males presented a higher proportion in August 2020 (females: 0.12% VS males: 0.58%). Differences in the rate of seropositivity between urban areas and the rest of the country were also observed during the study period. The four-month infection fatality rate (IFR) was estimated to be 0.47%, while the respective case fatality rate (CFR) was at 1.89%. Our findings confirm low seroprevalence of COVID-19 in Greece during the study period. The young adults are presented as the most affected age group. The loss of the cumulative effect of seropositivity in a proportion of previous SARS-CoV-2 infections was indicated. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Συγγραφείς:
Bogogiannidou, Z.
Speletas, M.
Vontas, A.
Nikoulis, D.J.
Dadouli, K.
Kyritsi, M.A.
Mouchtouri, V.A.
Mina, P.
Anagnostopoulos, L.
Koureas, M.
Karavasilis, V.
Nikou, O.
Pinaka, O.
Thomaidis, P.C.
Kadoglou, K.
Bedevis, K.
Spyrou, N.
Eleftheriou, A.A.
Papaevangelou, V.
Gikas, A.
Vatopoulos, A.
Ntzani, E.E.
Prezerakos, P.
Tsiodras, S.
Hadjichristodoulou, C.
Λέξεις-κλειδιά:
immunoglobulin G antibody; SARS-CoV-2 antibody, adult; aged; Article; case fatality rate; chemiluminescent microparticle immunoassay; child; controlled study; coronavirus disease 2019; cross-sectional study; female; geographic distribution; Greece; human; immune response; infection fatality rate; major clinical study; male; mortality; nonhuman; sensitivity and specificity; seroepidemiology; seroprevalence; Severe acute respiratory syndrome coronavirus 2
